^
Association details:
| Biomarker: | FGFR3 mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.
Published date:
02/14/2020
Excerpt:
Exploratory analysis of pts with FGFR3 DNA alterations (4 spot mutations and fusions) showed ORRs of 52.4% with rogaratinib and 26.7% with CT.
Secondary therapy:
vinflunine; paclitaxel; docetaxel
Trial ID:
Source:
Title:
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/ 3 mRNA Expression
Published date:
10/14/2022
Excerpt:
Exploratory analysis of patients with FGFR3 DNA alterations showed ORRs of 52.4% (11/21; 95% CI, 29.8 to 74.3) for rogaratinib and 26.7% (4/15; 95% CI, 7.8 to 55.1) for chemotherapy.
DOI:
10.1200/JCO.21.02303
Trial ID:
Source:
Title:
Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.
Excerpt:
Selected patients were treated with rogaratinib 800mg twice daily...Eleven of 12 pts with a PR were positive for FGFR3 mRNA, 5 of whom also had FGFR3 mutations, and one patient was positive for FGFR1 mRNA.
DOI:
10.1200/JCO.2018.36.6_suppl.494
Trial ID:
